Tau-targeting therapies present significant challenges due to the incomplete understanding of AD, the lack of robust and sensitive biomarkers for accurate diagnosis and treatment monitoring, and the difficulty of overcoming the blood-brain barrier [2]. Here, MAPT is linked to Alzheimer disease.